Figure 2.

The efficacy of adalimumab (D2E7), as determined by tender and swollen joint counts, could be recognized within 2 weeks when the agent was injected intravenously (IV) but not until 12 weeks when injected subcutaneously (SC). Baseline values were standardized to 100%. Data on file, Abbott Laboratories, Abbott Park, IL, USA.

Schwartzman and Morgan Arthritis Res Ther 2004 6(Suppl 2):S19-S23   doi:10.1186/ar996